Integral Molecular, a company that develops vaccines and therapeutics, announced a five-year $8 million contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID).
The funding will be used to support the company's continuing research into emerging viruses recognized as potential pandemic threats.
This marks the fourth similar contract awarded...
